245 related articles for article (PubMed ID: 30300141)
21. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells.
He D; Li H; Yusuf N; Elmets CA; Li J; Mountz JD; Xu H
J Immunol; 2010 Mar; 184(5):2281-8. PubMed ID: 20118280
[TBL] [Abstract][Full Text] [Related]
22. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
23. Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation.
Takahashi S; Minnie SA; Ensbey KS; Schmidt CR; Sekiguchi T; Legg SRW; Zhang P; Koyama M; Olver SD; Collinge AD; Keshmiri S; Comstock ML; Varelias A; Green DJ; Hill GR
Blood; 2024 Apr; 143(16):1656-1669. PubMed ID: 38295333
[TBL] [Abstract][Full Text] [Related]
24. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.
Blazar BR; Lees CJ; Martin PJ; Noelle RJ; Kwon B; Murphy W; Taylor PA
J Immunol; 2000 Nov; 165(9):4901-9. PubMed ID: 11046015
[TBL] [Abstract][Full Text] [Related]
25. Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion.
Mariani S; Coscia M; Even J; Peola S; Foglietta M; Boccadoro M; Sbaiz L; Restagno G; Pileri A; Massaia M
Br J Haematol; 2001 Jun; 113(4):1051-9. PubMed ID: 11442502
[TBL] [Abstract][Full Text] [Related]
26. IFN-gamma inhibits IL-4-induced type 2 cytokine expression by CD8 T cells in vivo and modulates the anti-tumor response.
Apte SH; Groves P; Olver S; Baz A; Doolan DL; Kelso A; Kienzle N
J Immunol; 2010 Jul; 185(2):998-1004. PubMed ID: 20562261
[TBL] [Abstract][Full Text] [Related]
27. Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.
Cooke RE; Gherardin NA; Harrison SJ; Quach H; Godfrey DI; Prince M; Koldej R; Ritchie DS
J Transl Med; 2016 Sep; 14(1):259. PubMed ID: 27599546
[TBL] [Abstract][Full Text] [Related]
28. Cancer-testis antigen 7 expression and immune responses following allogeneic stem cell transplantation for multiple myeloma.
Tyler EM; Jungbluth AA; Gnjatic S; O'Reilly RJ; Koehne G
Cancer Immunol Res; 2014 Jun; 2(6):547-58. PubMed ID: 24894092
[TBL] [Abstract][Full Text] [Related]
29. NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease.
Mastaglio S; Genovese P; Magnani Z; Ruggiero E; Landoni E; Camisa B; Schiroli G; Provasi E; Lombardo A; Reik A; Cieri N; Rocchi M; Oliveira G; Escobar G; Casucci M; Gentner B; Spinelli A; Mondino A; Bondanza A; Vago L; Ponzoni M; Ciceri F; Holmes MC; Naldini L; Bonini C
Blood; 2017 Aug; 130(5):606-618. PubMed ID: 28637663
[TBL] [Abstract][Full Text] [Related]
30. High Frequencies of Anti-Host Reactive CD8+ T Cells Ignore Non-Hematopoietic Antigen after Bone Marrow Transplantation in a Murine Model.
Gassa A; Kalkavan H; Jian F; Duhan V; Khairnar V; Shaabani N; Honke N; Carpinteiro A; Botezatu L; Crivello P; Dolff S; Ferencik S; Häussinger D; Khandanpour C; Fleischhauer K; Witzke O; Wahlers T; Hardt C; Lang PA; Lang KS
Cell Physiol Biochem; 2016; 38(4):1343-53. PubMed ID: 27007114
[TBL] [Abstract][Full Text] [Related]
31. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
[TBL] [Abstract][Full Text] [Related]
32. Myeloma-induced alloreactive T cells arising in myeloma-infiltrated bones include double-positive CD8+CD4+ T cells: evidence from myeloma-bearing mouse model.
Freeman LM; Lam A; Petcu E; Smith R; Salajegheh A; Diamond P; Zannettino A; Evdokiou A; Luff J; Wong PF; Khalil D; Waterhouse N; Vari F; Rice AM; Catley L; Hart DN; Vuckovic S
J Immunol; 2011 Oct; 187(8):3987-96. PubMed ID: 21908738
[TBL] [Abstract][Full Text] [Related]
33. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma.
Orsini E; Alyea EP; Chillemi A; Schlossman R; McLaughlin S; Canning C; Soiffer RJ; Anderson KC; Ritz J
Biol Blood Marrow Transplant; 2000; 6(4):375-86. PubMed ID: 10917573
[TBL] [Abstract][Full Text] [Related]
34. Synergistic effect of adoptive T-cell therapy and intratumoral interferon gamma-inducible protein-10 transgene expression in treatment of established tumors.
Huang H; Liu Y; Xiang J
Cell Immunol; 2002; 217(1-2):12-22. PubMed ID: 12425997
[TBL] [Abstract][Full Text] [Related]
35. Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells.
Bonanni V; Antonangeli F; Santoni A; Bernardini G
J Immunother Cancer; 2019 Nov; 7(1):290. PubMed ID: 31699153
[TBL] [Abstract][Full Text] [Related]
36. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.
Ito M; Shizuru JA
Biol Blood Marrow Transplant; 1999; 5(6):357-68. PubMed ID: 10595813
[TBL] [Abstract][Full Text] [Related]
37. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.
Guillerey C; Nakamura K; Pichler AC; Barkauskas D; Krumeich S; Stannard K; Miles K; Harjunpää H; Yu Y; Casey M; Doban AI; Lazar M; Hartel G; Smith D; Vuckovic S; Teng MW; Bergsagel PL; Chesi M; Hill GR; Martinet L; Smyth MJ
JCI Insight; 2019 Jun; 5(14):. PubMed ID: 31194697
[TBL] [Abstract][Full Text] [Related]
39. Early regulation of CD8 T cell alloreactivity by CD4+CD25- T cells in recipients of anti-CD154 antibody and allogeneic BMT is followed by rapid peripheral deletion of donor-reactive CD8+ T cells, precluding a role for sustained regulation.
Fehr T; Takeuchi Y; Kurtz J; Wekerle T; Sykes M
Eur J Immunol; 2005 Sep; 35(9):2679-90. PubMed ID: 16082727
[TBL] [Abstract][Full Text] [Related]
40. TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice.
Minnie SA; Waltner OG; Ensbey KS; Olver SD; Collinge AD; Sester DP; Schmidt CR; Legg SR; Takahashi S; Nemychenkov NS; Sekiguchi T; Driessens G; Zhang P; Koyama M; Spencer A; Holmberg LA; Furlan SN; Varelias A; Hill GR
J Clin Invest; 2023 Feb; 133(4):. PubMed ID: 36512425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
